Literature DB >> 16426949

Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.

Michael J Sweeting1, Daniela De Angelis, Keith R Neal, Mary E Ramsay, William L Irving, Mark Wright, Lisa Brant, Helen E Harris.   

Abstract

OBJECTIVES: To estimate hepatitis C virus (HCV) progression rates between disease stages prior to cirrhosis, using data from liver biopsies in three observational cohorts. To demonstrate how the method of cohort recruitment can influence the estimation of HCV-progression rates. STUDY DESIGN AND
SETTING: Data came from three United Kingdom observational cohorts, assembled from different referral sources. In total, 987 HCV-infected patients with an estimated (or known) date of infection and at least one histologically scored liver biopsy were eligible for inclusion in the analysis. Liver biopsy scores were used to determine the stage of HCV-related liver disease. A three-state continuous time Markov model was used to estimate covariate-specific average probabilities of progression of disease.
RESULTS: After adjusting for confounders, considerably different rates of disease progression were estimated in the three cohorts. For a group of patients with the same demographics, the estimated 20-year probability of progression to cirrhosis was 12% (95% confidence interval CI = 6-22) in a hospital-based cohort, 6% (95% CI = 3-13) in a posttransfusion cohort, and 23% (95% CI = 14-37) in a cohort recruited from a tertiary referral center.
CONCLUSION: Researchers using estimates of disease progression should be aware that the method of cohort recruitment has considerable influence on the progression rates that are derived.

Entities:  

Mesh:

Year:  2006        PMID: 16426949     DOI: 10.1016/j.jclinepi.2005.06.008

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  14 in total

Review 1.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

2.  Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis.

Authors:  Dena L Schanzer; Dana Paquette; Lisa M Lix
Journal:  CMAJ Open       Date:  2014-07-22

3.  Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.

Authors:  Tianhua He; Kan Li; Mark S Roberts; Anne C Spaulding; Turgay Ayer; John J Grefenstette; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391

4.  Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.

Authors:  Ilanca Fraser; Johanita Burger; Martie Lubbe; George Dranitsaris; Mark Sonderup; Tienie Stander
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

5.  Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

Authors:  Erica Villa; Ranka Vukotic; Calogero Cammà; Salvatore Petta; Alfredo Di Leo; Stefano Gitto; Elena Turola; Aimilia Karampatou; Luisa Losi; Veronica Bernabucci; Annamaria Cenci; Simonetta Tagliavini; Enrica Baraldi; Nicola De Maria; Roberta Gelmini; Elena Bertolini; Maria Rendina; Antonio Francavilla
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

6.  Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study.

Authors:  H E Harris; A Costella; G Amirthalingam; G Alexander; M E B Ramsay; N Andrews
Journal:  Epidemiol Infect       Date:  2011-11-29       Impact factor: 2.451

7.  Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.

Authors:  Scott A McDonald; Maznah Dahlui; Rosmawati Mohamed; Herlianna Naning; Fatiha Hana Shabaruddin; Adeeba Kamarulzaman
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

8.  Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.

Authors:  Swee Lin G Chen Yi Mei; Alexander J Thompson; Britt Christensen; Georgina Cunningham; Lucy McDonald; Sally Bell; David Iser; Tin Nguyen; Paul V Desmond
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

9.  Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study.

Authors:  Keith R Neal; Sheena Ramsay; Brian J Thomson; William L Irving
Journal:  Gut       Date:  2007-03-07       Impact factor: 23.059

10.  Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.

Authors:  C Canavan; J Eisenburg; L Meng; K Corey; C Hur
Journal:  Dig Dis Sci       Date:  2013-05-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.